docosahexaenoic acid
Small moleculeexperimental
Docosahexaenoic acid (DHA) is an omega−3 fatty acid that is an important component of the human brain, cerebral cortex, skin, and retina. It is given the fatty acid notation 22:6(n−3). It can be synthesized from alpha-linolenic acid or obtained directly from maternal milk (breast milk), fatty fish, fish oil, or algae oil. The consumption of DHA (e.g., from fatty fish such as salmon, herring, mackerel and sardines) contributes to numerous physiological benefits, including cognition. As a component of neuronal membranes, the function of DHA is to support neuronal conduction and to allow the optimal functioning of neuronal membrane proteins (such as receptors and enzymes). — Wikipedia
Clinical trial activity
78 trials · 110 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
12
Phase 3
3
Phase 4
8
Earliest trial started Mar 31, 2003 (NCT00530244)
Timeline
Indications
Approved for
Studied for
- Aging · Phase 2
- Alopecia · Early Phase 1
- Alzheimer Disease · Phase 2
- Amblyopia · Phase 1/Phase 2
- Arrhythmias, Cardiac · Phase 2/Phase 3
- Bariatric Surgery · Early Phase 1
- Biological Availability · Phase 4
- Bipolar Disorder · Phase 2
- Brain · Phase 4
- Breast Neoplasms · Phase 2
- Cognition · Phase 4
- Cognition Disorders · Phase 1/Phase 2
- Cognitive Dysfunction · Phase 2
- Craniocerebral Trauma · Phase 2
- Deficiency Diseases · Phase 2
- Diabetes Mellitus · Phase 4
- Diabetes Mellitus, Type 2 · Phase 4
- Enterocolitis, Necrotizing · Phase 2
- Fatty Acids, Omega-3 · Phase 2
- Fatty Liver · Early Phase 1
- Fetal Growth Retardation · Phase 3
- Healthy Volunteers · Phase 4
- Hypertriglyceridemia · Phase 4
- Lipid Metabolism Disorders · Early Phase 1
- Malnutrition · Phase 2
- Neurosciences · Phase 4
- Obstetric Labor, Premature · Phase 4
- Pediatric Obesity · Phase 4
- Pharmacokinetics · Phase 4
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
- Pre-Eclampsia · Phase 3
- Pregnancy Complications · Phase 2
- Premature Birth · Phase 3
- Stillbirth · Phase 3
- Work of Breathing · Phase 3
Mechanism of action
- Unspecified targetUnclear
Unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaDocosahexaenoic acid ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07012486 | Early Phase 1 (Phase 1) | Jun 30, 2025 | Fudan University |
| NCT07096466 | N/A | Jun 23, 2025 | Amazentis SA |
| NCT06736925 | Phase 2 | Jan 31, 2025 | Indiana University, National Institute of Neurological Disorders and Stroke (NINDS) |
| NCT06494488 | Early Phase 1 (Phase 1) | Aug 1, 2024 | Brown University, National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH) |
| NCT06207071 | N/A | May 20, 2024 | Mead Johnson, University of Alabama, Birmingham |
| NCT06848101 | N/A | Mar 15, 2024 | University of Illinois |
| NCT06302023 | Phase 4 | Mar 1, 2024 | KhonKaen University |
| NCT06294067 | N/A | Feb 26, 2024 | Unity Health Toronto, University of Toronto |
| NCT06129526 | Phase 4 | Dec 31, 2023 | University of Ioannina |
| NCT05915806 | N/A | Jul 30, 2023 | Canadian Institutes of Health Research (CIHR), Laval University, McGill University, South Australian Health and Medical Research Institute, St. Justine's Hospital, University of British Columbia |
| NCT06981676 | N/A | Jul 25, 2023 | Pontificia Universidad Catolica de Chile |
| NCT06833554 | N/A | Jan 1, 2023 | Government of Spain |
| NCT05438173 | N/A | Jul 11, 2022 | MB Clinical Research and Consulting LLC, Midwest Center for Metabolic and Cardiovascular Research, Naturmega |
| NCT05191823 | N/A | Dec 1, 2021 | National Institutes of Health (NIH), Ohio State University |
| NCT04496817 | N/A | Nov 1, 2021 | Egg Farmers of Canada, University of Manitoba |
| NCT05038462 | N/A | Sep 30, 2021 | Fundació Sant Joan de Déu, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona |
| NCT05427604 | N/A | Feb 23, 2021 | Université catholique de Louvain |
| NCT05841927 | N/A | Dec 1, 2020 | Fudan University |
| NCT04460287 | N/A | Jul 30, 2020 | Faculty of Medicine Universitas Indonesia - Dr Cipto Mangunkusumo Hospital, Indonesian Nutrition Association |
| NCT04175769 | N/A | Jan 31, 2020 | University of Alberta, University of Calgary |
Showing 20 of 78 trials
Page 1 / 4
Organizations
Research & Development (110)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| DSM | For profit | 5 | 1 | 2 | 2005 |
| BASF | For profit | 3 | 1 | 1 | 2017 |
| Fudan University | Academic/Hospital | 3 | 3 | 3 | 2019 |
| National Institutes of Health (NIH) | Government | 3 | 0 | 2 | 2019 |
| SCF Pharma | For profit | 3 | 3 | 1 | 2018 |
| Ain Shams University | Academic/Hospital | 2 | 2 | 1 | 2017 |
| Canadian Institutes of Health Research (CIHR) | Academic/Hospital | 2 | 0 | 2 | 2019 |
| Government of Mexico | Government | 2 | 2 | 1 | 2010 |
| Indiana University | Academic/Hospital | 2 | 2 | 2 | 2010 |
| Instituto Mexicano del Seguro Social | Government | 2 | 0 | 1 | 2010 |
| Laval University | Academic/Hospital | 2 | 1 | 1 | 2018 |
| MB Clinical Research and Consulting LLC | For profit | 2 | 0 | 2 | 2018 |
| Mead Johnson | For profit | 2 | 1 | 1 | 2024 |
| Midwest Center for Metabolic and Cardiovascular Research | Academic/Hospital | 2 | 2 | 2 | 2018 |
| Northumbria University | Academic/Hospital | 2 | 2 | 1 | 2017 |
| Ohio State University | Academic/Hospital | 2 | 2 | 1 | 2018 |
| Pontificia Universidad Catolica de Chile | Academic/Hospital | 2 | 2 | 2 | 2015 |
| University of Alberta | Academic/Hospital | 2 | 0 | 2 | 2019 |
| University of Calgary | Academic/Hospital | 2 | 2 | 2 | 2019 |
| University of Milan | Academic/Hospital | 2 | 2 | 2 | 2005 |
110 organizations
Page 1 / 6